F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)

• Conditions: Acute Myeloid Leucemia

• Registration Number: NCT01592266
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution. Highly increased uptake of this radiopharmaceutical was shown in a number of hematologic disease either in bone marrow or extramedullary.

F18-FLT PET/CT can provide a tool for whole body assessment of activity in bone marrow as well as early estimation of treatment efficacy or lack of it. In addition, this noninvasive study can replace bone marrow biopsy and predict response vs. non response to therapy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2012-04
• Study First Submitted: 2012-04-16
• Study First Submitted QC: 2012-05-03
• Last Update Submitted: 2012-05-03
• Study First Posted: 2012-05-07
• Last Update Posted: 2012-05-07
• Study Start: 2012-10
• Primary Completion: 2013-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• new diagnosis of AML

Exclusion Criteria

• pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measure of extent and intensity ( by standardized uptake value - SUV) of disease in bone marrow demonstrated on PET/CT images before and after treatment.

Secondary Outcome Measures

Name	Time	Method
prediction of treatment response by dynamics of FLT uptake(by SUV)in comparison to bone marrow biopsy

Trial Locations

Locations (1)

Hadassah Hebrew University Medical Center; 🇮🇱 Jerusalem, Israel